| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.56B | 3.60B | 3.54B | 3.76B | 3.99B |
| Gross Profit | 1.01B | 1.56B | 1.47B | 356.70M | 1.51B | 1.27B |
| EBITDA | 238.37M | 243.89M | 217.89M | 202.22M | 198.58M | -54.04M |
| Net Income | 99.17M | 92.36M | 140.96M | 104.75M | 61.16M | -134.70M |
Balance Sheet | ||||||
| Total Assets | 3.28B | 3.10B | 2.91B | 2.75B | 2.99B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 447.26M | 402.00M | 478.81M | 609.04M | 796.89M | 719.99M |
| Total Debt | 938.79M | 675.15M | 635.42M | 645.95M | 880.25M | 732.84M |
| Total Liabilities | 2.62B | 2.44B | 2.33B | 2.27B | 2.64B | 2.64B |
| Stockholders Equity | 657.35M | 652.32M | 568.29M | 476.20M | 333.96M | 278.74M |
Cash Flow | ||||||
| Free Cash Flow | 11.93M | -37.54M | -90.14M | 89.41M | -116.34M | -222.42M |
| Operating Cash Flow | 76.93M | 43.16M | -30.37M | 128.13M | -69.25M | -161.53M |
| Investing Cash Flow | -68.67M | -96.71M | 17.71M | 170.87M | -123.25M | -31.81M |
| Financing Cash Flow | 50.26M | -23.91M | -99.08M | -294.33M | 107.42M | 4.16M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $1.24B | 12.46 | 15.36% | 1.33% | 1.87% | -26.72% | |
| ― | CHF2.03B | 34.10 | ― | 1.30% | -3.67% | -12.95% | |
| ― | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
| ― | CHF163.08M | 17.06 | ― | 3.18% | -1.46% | -115.85% | |
| ― | CHF2.01B | 62.97 | ― | 0.99% | -6.87% | -74.29% | |
| ― | CHF455.11M | -11.69 | ― | 58.15% | -28.40% | -117.97% |
Implenia has successfully issued a CHF 180 million bond on the Swiss capital market, with a 5-year term and a 2.05% interest rate, to refinance existing debts and strengthen its financing structure. The bond issuance, which will be listed on the SIX Swiss Exchange, is expected to enhance Implenia’s financial stability and extend its maturity profile, potentially benefiting stakeholders by ensuring continued operational strength and market positioning.
The most recent analyst rating on (CH:IMPN) stock is a Buy with a CHF74.00 price target. To see the full list of analyst forecasts on Implenia AG stock, see the CH:IMPN Stock Forecast page.
Implenia has secured new building construction contracts in Germany, totaling over EUR 200 million, aligning with its strategic focus on large and complex real estate projects. These projects include the development of a high-quality office district in Munich, a new administrative building in Brandenburg, and various residential, industrial, sports, and school facilities, showcasing Implenia’s expertise and commitment to sustainable and innovative construction solutions.
The most recent analyst rating on (CH:IMPN) stock is a Buy with a CHF74.00 price target. To see the full list of analyst forecasts on Implenia AG stock, see the CH:IMPN Stock Forecast page.
Implenia AG is a Swiss-based company operating in the construction and real estate sectors, known for its expertise in complex infrastructure and building projects across Europe.
Implenia AG reported a positive first half of 2025 with a 12.9% increase in EBIT to CHF 57 million and a 6.6% rise in revenue to CHF 1.86 billion. The order backlog grew by 9.8% to CHF 7.78 billion, driven by significant projects in tunnel and bridge construction, and real estate. The company’s strategic focus on high-margin sectors and diversification across markets and services has strengthened its market position and financial stability, with expectations to achieve an EBIT target of CHF 140 million for the full year.
The most recent analyst rating on (CH:IMPN) stock is a Buy with a CHF62.00 price target. To see the full list of analyst forecasts on Implenia AG stock, see the CH:IMPN Stock Forecast page.
Implenia AG has secured building construction contracts worth over CHF 400 million, aligning with its strategy of focusing on specialized real estate projects. These contracts include the construction of a new research and training center for medicine at the University of Bern and a residential development in Zurich Oberland. The projects reflect Implenia’s commitment to leveraging its comprehensive expertise and experience in delivering large, complex projects. The new contracts are expected to enhance Implenia’s market positioning and demonstrate its capability in handling diverse construction projects, benefiting stakeholders through sustainable and innovative solutions.
The most recent analyst rating on (CH:IMPN) stock is a Buy with a CHF41.00 price target. To see the full list of analyst forecasts on Implenia AG stock, see the CH:IMPN Stock Forecast page.